Clinical Chemistry Analyzers Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Clinical Chemistry Analyzers Market size was valued at USD 15.2 billion in 2023 and is estimated to grow at a CAGR of 4.1% between 2024 and 2032. Clinical chemistry analyzers are medical devices used in laboratories to perform chemical analysis of various substances present in biological samples such as blood, serum, plasma, urine, and other bodily fluids. These analyzers utilize advanced techniques and technologies to measure a wide range of biochemical parameters, including electrolytes, enzymes, proteins, metabolites, hormones, lipids, and drugs.
The increasing prevalence of chronic disorders and lifestyle diseases has emerged as a significant driver for the market. For instance, according to the World Health Organization (WHO) 2023 report, noncommunicable diseases (NCDs) accounted for the deaths of 41 million individuals each year, making up about 74% of all global fatalities. Therefore, there is a surge in demand for enhanced monitoring and treatment options, innovative medical technologies, and comprehensive programs for managing conditions such as cardiovascular diseases, diabetes, obesity, and related disorders.
Furthermore, growing adoption of point of care testing signifies a shift towards convenient and rapid diagnostic capabilities, increasing geriatric population, increasing demand for laboratory automation within clinical laboratory services which is estimated to reach USD 409.9 billion by 2032 highlights the need for improving efficiency and scalability in diagnostic testing, among other contributing factors propelling the growth of the market.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Clinical Chemistry Analyzers Market Size in 2023: | USD 15.2 Billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2023 - 2032 CAGR: | 4.1 |
2023 Value Projection: | USD 21.5 Billion |
Historical Data for: | 2018 – 2023 |
No of Pages: | 200 |
Tables, Charts & Figures: | 343 |
Segments Covered: | Product, Test Type, Modality, End-use, and Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
Growing adoption of point of care testing (POCT) in clinical chemistry analyzers signifies a paradigm shift in healthcare delivery, bringing diagnostic testing closer to the patient, improving access to timely and accurate diagnostic information, and ultimately revolutionizing the way healthcare is delivered and managed.
Based on product, the market is classified into reagents, analyzers, and other products. The reagents are sub segmented into buffers, calibrators, controls, standards, and other reagents. The analyzers are sub segmented into technology and type. The reagents segment held a market size of 8.2 billion in 2023.
Based on test type, the clinical chemistry analyzers market is bifurcated into basic metabolic panel, liver panel, renal profile, lipid profile, thyroid function panel, electrolyte panel, and specialty chemical tests. The basic metabolic panel segment is estimated to account for a market size of USD 4 billion by 2032.
Based on modality, the clinical chemistry analyzers market is categorized into centralized and decentralized. The centralized segment accounted for around USD 6.6 billion revenue size in 2023.
Based on end-use, the clinical chemistry analyzers market is categorized into hospitals and clinics, specialty clinics, diagnostic laboratories, and other end-users. The hospitals and clinics segment accounted for around USD 5.7 billion revenue size in 2023.
North America clinical chemistry analyzers market accounted for USD 6.5 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
The clinical chemistry analyzers industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced devices based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
Some of the eminent market participants operating in the clinical chemistry analyzers industry include:
Market, By Product
Market, By Test Type
Market, By Modality
Market, By End-use
The above information is provided for the following regions and countries:
North America clinical chemistry analyzers industry accounted for USD 6.5 billion revenue in 2023, attributed to growing prevalence of chronic disorders such cardiovascular diseases, diabetes, and cancer.
Abbott Laboratories, Danaher Corporation, EKF Diagnostics, F.Hoffmann-La Roche Ltd., Hitachi Ltd., HORIBA Ltd., Ortho Clinical Diagnostics, QuidelOrtho Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Sysmex Corporation, and Thermo Fisher Scientific Inc.
The global clinical chemistry analyzers market was valued at USD 15.2 billion in 2023 and is estimated to record a CAGR of 4.1% between 2024 and 2032, driven by the increasing prevalence of chronic disorders and lifestyle diseases.
The centralized segment accounted for around USD 6.6 billion revenue size in 2023, as it offers numerous advantages in terms of efficiency, cost-effectiveness, space-saving, standardization, quality control, integration, and scalability.